Abstract
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Keywords: Left ventricular dysfunction, doxorubicin, oxidant stress.
Related Books
Cardiac Resynchronization Therapy: An Established Pacing Therapy for Heart Failure and Mechanical Dyssynchrony
Cardiac Care and COVID-19: Perspectives in Medical Practice
4D Fetal Echocardiography
Frontiers in Myocardia
Frontiers in Myocardia
Frontiers in Myocardia
Latest Advances in Clinical and Pre-Clinical Cardiovascular MRI
Electrocardiography (ECG)
Degenerative Aortic Valve Disease, its Mechanism on Progression, its Effect on the Left Ventricle and the Postoperative Results
Focus Concise Animated Dictionary of Cardiology
7